Gwangju, South Korea

Sooyeon Song

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: The Penn State Research Foundation. Active years: 2023-2025.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2023-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Sooyeon Song: Innovator in Antibiotic Resistance Solutions

Introduction

Sooyeon Song is a prominent inventor based in Gwangju, South Korea. She has made significant contributions to the field of antibiotic resistance, focusing on methods to combat antibiotic-tolerant bacteria. With a total of 2 patents, her work is crucial in addressing the growing concern of persistent bacterial infections.

Latest Patents

Sooyeon Song's latest patents include innovative methods for killing antibiotic-tolerant bacteria. These patents disclose compounds, compositions, and methods for treating infections caused by bacteria. In particular, the disclosed compounds and methods are designed to effectively target and eliminate persister bacteria that survive antibiotic treatment and can lead to recurrent infections.

Career Highlights

Sooyeon Song is affiliated with the Penn State Research Foundation, where she continues her research and development efforts. Her work is instrumental in advancing the understanding and treatment of bacterial infections, particularly those that are resistant to conventional antibiotics.

Collaborations

Sooyeon collaborates with Thomas Keith Wood, enhancing her research through shared expertise and innovative ideas. Their partnership is vital in pushing the boundaries of current knowledge in the field of antibiotic resistance.

Conclusion

Sooyeon Song's contributions to the field of antibiotic resistance are invaluable. Her innovative methods and dedication to research play a significant role in the fight against persistent bacterial infections.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…